Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
observational monocentric study
observational monocentric study
Primary objective :
Describe post-cancer supportive care needs, assessed by questionnaire in patients treated for breast cancer after completion of treatment and 2 years later.
Secondary objective :
Schedule :
The selected patients then received a letter including an information and non-objection note, the post-cancer needs questionnaire, the Fear Inventory severity subscale questionnaire, and the QLQ-C30 questionnaire. A delay of 1 month was chosen to return the questionnaire with a phone call after 15 days for an analysis of responses in February 2019.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| women treated for breast cancer in 2017 (cohort A) | all patients who completed breast cancer treatment between January 1 and May 31, 2017. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random | ||
| women treated for breast cancer in 2015 (cohorte B) | all patients who completed breast cancer treatment between January 1 and 31 May 2015. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Post-cancer needs analysis | Post-cancer needs analysis based on the "post-cancer needs assessment" questionnaire for patients in both cohorts | 2 years |
Not provided
Not provided
Inclusion Criteria:
Women who have been treated for breast cancer and whose treatment ended in 2017 (cohort A) and in 2015 (cohort B), aged between 18 and 80 years, and who declared their non-opposition free and enlightened.
Exclusion Criteria:
Patients who have been treated for recurrence or 2nd cancer, metastases from the outset, male, refusal to participate.
Not provided
Not provided
patients who completed breast cancer treatment between January 1 and May 31, 2017, and between January 1 and 31 May 2015. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random in each of the 2 cohorts.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| stephanie SERVAGI VERNAT, MD | Institut Jean-Godinot | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Jean Godinot | Reims | 51100 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000719212 | Pathophobia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided